Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy

Table 2 Recommendations of international guidelines for treatment and follow-up in different clinical scenarios

	AASLD 2018	EASL 2017	APASL 2016	AGA 2015
Screening before chemotherapy/immunosuppressive therapy	HBsAg and anti-HBc	HBsAg, anti-HBc, and anti-HBs	HBsAg and anti-HBc	HBsAg and anti-HBc
				HBV DNA if serology positive
Start antiviral prophylaxis before chemotherapy/immunosuppressive therapy	For HBsAg (+) patients	For HBsAg (+) patients	For HBsAg (+) patients	For HBsAg (+) patients
		For HBsAg (-)/anti-HBc (+) patients: if at high risk of HBV reactivation	For HBsAg (-)/anti-HBc (+) patients: if detectable serum HBV DNA	For HBsAg (-)/anti-HBc (+) patients: If the chemotherapy is associated with high or moderate risk of HBV reactivation
Treatment duration of antiviral treatment after completing chemotherapy/immunosuppressive therapy	At least 6 mo	12 mo	12 mo	At least 6 mo
	At least 12 mo for patients receiving anti-CD20 antibodies therapy			At least 12 mo for patient receiving anti-CD20 antibodies therapy
Antivirals of choice	TDF, TAF or ETV	TDF, TAF or ETV	TDF and ETV	TDF and ETV

AASLD: American Association for the Study of Liver Diseases; AGA: American gastroenterology association; anti-HBc: Hepatitis B core antibodies; APASL: Asian pacific association for the study of the liver; EASL: European association for the study of the liver; ETV: Entecavir; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus; TAF: Tenofovir alafenamide; TDF: Tenofovir disoproxil fumarate.